(Circulation. 1999;99:817-822.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Cardioprotective Effect of Angiotensin-Converting Enzyme Inhibition Against Hypoxia/Reoxygenation Injury in Cultured Rat Cardiac Myocytes
From the Second Department of Medicine, Kyoto Prefectural University of Medicine and Department of Clinical Pharmacology (J.A.), Kyoto Pharmaceutical University, Kyoto, Japan.
Correspondence to Tetsuya Tatsumi, MD, PhD, Second Department of Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. E-mail tatsumi{at}koto.kpu-m.ac.jp
Background—Although ACE inhibitors can protect myocardium against ischemia/reperfusion injury, the mechanisms of this effect have not yet been characterized at the cellular level. The present study was designed to examine whether an ACE inhibitor, cilazaprilat, directly protects cardiac myocytes against hypoxia/reoxygenation (H/R) injury.
Methods and Results—Neonatal rat cardiac myocytes in primary culture were exposed to hypoxia for 5.5 hours and subsequently reoxygenated for 1 hour. Myocyte injury was determined by the release of creatine kinase (CK). Both cilazaprilat and bradykinin significantly inhibited CK release after H/R in a dose-dependent fashion and preserved myocyte ATP content during H/R, whereas CV-11974, an angiotensin II receptor antagonist, and angiotensin II did not. The protective effect of cilazaprilat was significantly inhibited by Hoe 140 (a bradykinin B2 receptor antagonist), NG-monomethyl-L-arginine monoacetate (L-NMMA) (an NO synthase inhibitor), and methylene blue (a soluble guanylate cyclase inhibitor) but not by staurosporine (a protein kinase C inhibitor), aminoguanidine (an inhibitor of inducible NO synthase), or indomethacin (a cyclooxygenase inhibitor). Cilazaprilat significantly enhanced bradykinin production in the culture media of myocytes after 5.5 hours of hypoxia but not in that of nonmyocytes. In addition, cilazaprilat markedly enhanced the cGMP content in myocytes during hypoxia, and this augmentation in cGMP could be blunted by L-NMMA and methylene blue but not by aminoguanidine.
Conclusions—The present study demonstrates that cilazaprilat can directly protect myocytes against H/R injury, primarily as a result of an accumulation of bradykinin and the attendant production of NO induced by constitutive NO synthase in hypoxic myocytes in an autocrine/paracrine fashion. NO modulates guanylate cyclase and cGMP synthesis in myocytes, which may contribute to the preservation of energy metabolism and cardioprotection against H/R injury.
Key Words: angiotensin • hypoxia • bradykinin • nitric oxide • myocytes
This article has been cited by other articles:
 |
|
 |
|
  K. Trescher, M. Bauer, W. Dietl, S. Hallstrom, N. Wick, M. Wolfsberger, R. Ullrich, G. Jurgens, E. Wolner, and B. K. Podesser Improved myocardial protection in the failing heart by selective endothelin-A receptor blockade J. Thorac. Cardiovasc. Surg., April 1, 2009; 137(4): 1005 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Arab, K. Kuemmerer, J. Wang, C. Bode, and C. Hehrlein Oxygenated Perfluorochemicals Improve Cell Survival during Reoxygenation by Pacifying Mitochondrial Activity J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 417 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kobara, N. Sunagawa, M. Abe, N. Tanaka, H. Toba, H. Hayashi, N. Keira, T. Tatsumi, H. Matsubara, and T. Nakata Apoptotic myocytes generate monocyte chemoattractant protein-1 and mediate macrophage recruitment J Appl Physiol, March 1, 2008; 104(3): 601 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ganitkevich, S. Reil, B. Schwethelm, T. Schroeter, and K. Benndorf Dynamic Responses of Single Cardiomyocytes to Graded Ischemia Studied by Oxygen Clamp in On-Chip Picochambers Circ. Res., July 21, 2006; 99(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wei, X. Wang, P. Kuukasjarvi, J. Laurikka, T. Rinne, E.-L. Honkonen, and M. Tarkka Bradykinin preconditioning in coronary artery bypass grafting Ann. Thorac. Surg., August 1, 2004; 78(2): 492 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tatsumi, J. Shiraishi, N. Keira, K. Akashi, A. Mano, S. Yamanaka, S. Matoba, S. Fushiki, H. Fliss, and M. Nakagawa Intracellular ATP is required for mitochondrial apoptotic pathways in isolated hypoxic rat cardiac myocytes Cardiovasc Res, August 1, 2003; 59(2): 428 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Yamanaka, T. Tatsumi, J. Shiraishi, A. Mano, N. Keira, S. Matoba, J. Asayama, S. Fushiki, H. Fliss, and M. Nakagawa Amlodipine inhibits doxorubicin-induced apoptosis in neonatal rat cardiac myocytes J. Am. Coll. Cardiol., March 5, 2003; 41(5): 870 - 878. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Podesser, J. Schirnhofer, O. Y. Bernecker, A. Kroner, M. Franz, S. Semsroth, B. Fellner, J. Neumuller, S. Hallstrom, and E. Wolner Optimizing Ischemia/Reperfusion in the Failing Rat Heart--Improved Myocardial Protection With Acute ACE Inhibition Circulation, September 24, 2002; 106(12_suppl_1): I-277 - I-283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-D. Wagner, V. Essmann, K. Mydlak, M. Wirth, G. Gmehling, J. Bohlender, H. M. Stauss, J. Gunther, I. Schimke, and H. Scholz Decreased susceptibility of cardiac function to hypoxia-reoxygenation in renin-angiotensinogen transgenic rats Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2002; 283(1): R153 - R160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Shiraishi, T. Tatsumi, N. Keira, K. Akashi, A. Mano, S. Yamanaka, S. Matoba, J. Asayama, T. Yaoi, S. Fushiki, et al. Important role of energy-dependent mitochondrial pathways in cultured rat cardiac myocyte apoptosis Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1637 - H1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Blais Jr., D. Fortin, J.-L. Rouleau, G. Molinaro, and A. Adam Protective Effect of Omapatrilat, a Vasopeptidase Inhibitor, on the Metabolism of Bradykinin in Normal and Failing Human Hearts J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 621 - 626. [Abstract] [Full Text]
|
|
|
|
|
|
S. Fischer, A. A. MacLean, M. Liu, B. Kalirai, and S. Keshavjee Inhibition of angiotensin-converting enzyme by captopril: A novel approach to reduce ischemia-reperfusion injury after lung transplantation J. Thorac. Cardiovasc. Surg., September 1, 2000; 120(3): 573 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-L. Pan, S.-R. Chen, G. M. Scicli, and O. A. Carretero Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H116 - H121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Marber Ischemic Preconditioning in Isolated Cells Circ. Res., May 12, 2000; 86(9): 926 - 931. [Full Text] [PDF]
|
|
|
|
|
|
F. Randsbaek, H.-H. Kimose, T. Bjerre, U. Moldrup, H. E. Botker, and T. T. Nielsen Captopril-induced glutamate release at the start of reperfusion after cold cardioplegic storage of pig hearts J. Thorac. Cardiovasc. Surg., May 1, 2000; 119(5): 1030 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tatsumi, S. Matoba, A. Kawahara, N. Keira, J. Shiraishi, K. Akashi, M. Kobara, T. Tanaka, M. Katamura, C. Nakagawa, et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1338 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Faggiotto and R. Paoletti Statins and Blockers of the Renin-Angiotensin System : Vascular Protection Beyond Their Primary Mode of Action Hypertension, October 1, 1999; 34(4): 987 - 996. [Abstract] [Full Text] [PDF]
|
|